A new Beginning..., page-1700

Afternoon all!

Lots of worry warts out there at the moment. Needn't fear Smartcough-C-2 is near!

IMO we will go into a trading halt this week...

I'm told that TK is off to Boston arriving on Monday US time, a little early then I would have thought as the connected health conference does not start until the 17th ( our Thursday) https://www.connectedhealthconf.org/boston/2018 . There has been no updated announcement today and I take this as a positive, meaning I believe a trading halt is imminent tomorrow or on Wednesday. Our company stated in the last update on the 27/09/18 "With high quality cough sound recordings and an objective, rigorous adjudication process, our pivotal US clinical study is in great shape and we look forward to reporting results in mid October"

Interestingly the Baim Institute is also located in Boston, whom Resapp have hired to undertake the study. Also our principal investigator Peter M. From MGH This information has been sourced from:

https//www.clinicaltrials.gov

Hmmmm...

For those who haven't viewed this video....



It highlights the need for RAP's technology particularly in the third world regions and in remote areas with thousands of kids passing away from pneumonia. However a diagnostic tool is just one piece of the puzzle as the shortage of oxygen is another amongst other things like antibiotics etc.  Our principal investigator Peter Moschovis makes an appearance and highlights the need for something like our technology, but didn't mention us specifically.

Anyways we're damn close now folks!

All this hard work going on behind the scenes should pay off:

"The SMARTCOUGH-C-2 study is a revision of ResApp’s earlier SMARTCOUGH-C study with significant improvements made to training and processes. Improvements in hospital staff training and an improved audio recording application has produced higher quality cough audio data in the SMARTCOUGH-C-2 study, subsequently verified by a rigorous quality assuranceprocess which found to date that less than 3% of recordings were unacceptable. An independent, centralised clinical adjudication panel and less subjective clinical case definitions are also being used to ensure consistent clinical diagnosis."

I like our chances this time based on the four points I highlighted in the above quote.


PS I can't stop thinking about those excellent results last week for obstructive sleep apnea. Our barrier to entry into the EU, AU and US markets will be far less scrutinized because there are no detrimental effects to ones health based on the results our machine learning algorithms present because it will just be a screening tool which ultimately just will alert the person to go and see a doctor for further testing. Also another reason is because you're not consuming any medication as there is no cure for OSA the only way, once diagnosed is to manage your obstructive sleep apnoea by purchasing or hiring a machine that helps you breathe better at night.  This upcoming screening tool, once the home sleep test study has been completed (HST) will be a major step forward in the quality of ones life.  80% of people with OSA don't even realise they have it which highlights the need for an instant screening tool. In my view what ResApp have will be more than just a screening tool judging from those excellent percentage outcomes detailed in the double blind prospective study. The machine learning algorithms will only improve from here as more test subjects feed the data set. If patience can skip the whole taking home a HST machine than we have the ability to become very disruptive. The upcoming results will determine if ResApp will charge $100  for a screening tool or $250 for a diagnostic tool IMO. Can't wait see how this progresses over the next couple of months...

All the best!

Cheers

Red bar